Ipatasertib-paclitaxel displays potential as first-line treatment for inoperable advanced TNBC

Treatment with ipatasertib plus paclitaxel in the first-line setting demonstrated a trend toward improved overall survival (OS) compared with paclitaxel alone in women with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC), according to final results of the phase II LOTUS trial.

Add-on lenalidomide makes no difference in older acute myeloid leukaemia patients
The addition of lenalidomide shows no clear benefit for older patients with acute myeloid leukaemia receiving treatment with standard remission induction chemotherapy, according to data from a phase II trial.
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in